Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18896732 | 1.00 | L3MBTL1 (0.32) | L3MBTL1 | |
| SCHEMBL7150032 | 1.00 | L3MBTL1 (0.32) | L3MBTL1 | |
| SCHEMBL18896733 | 1.00 | L3MBTL1 (0.32) | L3MBTL1 | |
| SCHEMBL7150825 | 1.00 | L3MBTL1 (0.32) | L3MBTL1 | |
| SCHEMBL383041 | 1.00 | L3MBTL1 (0.32) | L3MBTL1 | |
| SCHEMBL6100675 | 1.00 | L3MBTL1 (0.32) | L3MBTL1 | |
| SCHEMBL800535 | 0.87 | — | — | |
| SCHEMBL7155852 | 0.81 | LMNA (0.43) | — | |
| SCHEMBL7150241 | 0.81 | LMNA (0.43) | — | |
| SCHEMBL7145230 | 0.81 | LMNA (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012040126-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NTPCR, NUDT1 | L3MBTL1 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.